Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06117540

A Study of WX390 in Patients With Advanced Solid Tumors

An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid Tumors

Sponsor: Shanghai Jiatan Pharmatech Co., Ltd

Conditions Solid Tumor

Interventions WX390

Updated 4 times since 2023 Last updated: Nov 18, 2024 Started: May 11, 2021 Primary completion: Jun 12, 2025 Completion: Jun 12, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Solid Tumor and is currently actively recruiting participants. Shanghai Jiatan Pharmatech Co., Ltd leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Dec 2024 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

May 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Jiatan Pharmatech Co., Ltd

Data source: Shanghai Jiatan Pharmatech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China